Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene and Iressa in Third Line NSCLC
NCT00238628Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 2004
- Primary completion
- Apr 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bexarotene, gefitinib in non-small cell lung cancer (NSCLC), sponsored by Stanford University. Started Apr 2004; status: completed.
02
Drugs
bexarotenegefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00238628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238628.